HUP9600114A3 - 2,8-disubstituted quinazolinones and pharmaceutical compositions containing them - Google Patents

2,8-disubstituted quinazolinones and pharmaceutical compositions containing them

Info

Publication number: HUP9600114A3
Authority: HU; Hungary
Prior art keywords: pharmaceutical compositions; compositions containing; quinazolinones; disubstituted; disubstituted quinazolinones
Prior art date: 1995-01-19

Application number

HU9600114A

Other languages

English (en)

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-19

Filing date

1996-01-19

Publication date

2000-03-28

1996-01-19 Application filed by Bayer Ag filed Critical Bayer Ag

1996-03-28 Publication of HU9600114D0 publication Critical patent/HU9600114D0/hu

1996-12-30 Publication of HUP9600114A2 publication Critical patent/HUP9600114A2/hu

2000-03-28 Publication of HUP9600114A3 publication Critical patent/HUP9600114A3/hu

Links

AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Paints Or Removers (AREA)
Plural Heterocyclic Compounds (AREA)

HU9600114A 1995-01-19 1996-01-19 2,8-disubstituted quinazolinones and pharmaceutical compositions containing them HUP9600114A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19501481A DE19501481A1 (de)	1995-01-19	1995-01-19	2,8-Disubstituierte Chinazolinone

Publications (3)

Publication Number	Publication Date
HU9600114D0 HU9600114D0 (en)	1996-03-28
HUP9600114A2 HUP9600114A2 (en)	1996-12-30
HUP9600114A3 true HUP9600114A3 (en)	2000-03-28

Family

ID=7751829

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9600114A HUP9600114A3 (en)	1995-01-19	1996-01-19	2,8-disubstituted quinazolinones and pharmaceutical compositions containing them

Country Status (32)

Country	Link
US (1)	US5721238A (hu)
EP (1)	EP0722937A1 (hu)
JP (1)	JPH08253457A (hu)
KR (1)	KR960029325A (hu)
CN (1)	CN1134417A (hu)
AR (1)	AR006738A1 (hu)
AU (1)	AU704102B2 (hu)
BG (1)	BG100293A (hu)
BR (1)	BR9600148A (hu)
CA (1)	CA2167345A1 (hu)
CO (1)	CO4700522A1 (hu)
CZ (1)	CZ16796A3 (hu)
DE (1)	DE19501481A1 (hu)
EE (1)	EE9600019A (hu)
FI (1)	FI960227A (hu)
HR (1)	HRP960004A2 (hu)
HU (1)	HUP9600114A3 (hu)
IL (1)	IL116770A (hu)
IN (1)	IN184956B (hu)
MA (1)	MA23780A1 (hu)
NO (1)	NO307513B1 (hu)
NZ (1)	NZ280831A (hu)
PE (1)	PE66696A1 (hu)
PL (1)	PL312352A1 (hu)
RO (1)	RO117451B1 (hu)
RU (1)	RU2158733C2 (hu)
SG (1)	SG34377A1 (hu)
SK (1)	SK7796A3 (hu)
SV (1)	SV1996000005A (hu)
TR (1)	TR199600029A2 (hu)
YU (1)	YU1496A (hu)
ZA (1)	ZA96397B (hu)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2238283C (en)	1997-05-30	2002-08-20	Cell Pathways, Inc.	Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) *	1997-05-30	1999-01-12	Cell Pathways, Inc.	Method for identifying compounds for inhibition of cancerous lesions
US20020025969A1 (en) *	1997-07-09	2002-02-28	Wolf-Georg Forssmann	Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US6132757A (en)	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6110489A (en) *	1998-05-01	2000-08-29	Cutler; Neal R.	Use of quinolines and quinolones to treat male erectile dysfunction
US6194433B1 (en) *	1998-10-05	2001-02-27	Neal R. Cutler	Sexual dysfunction in females
US6187790B1 (en)	1999-03-04	2001-02-13	Neal R. Cutler	Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en)	2000-06-19	2002-07-30	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6132753A (en) *	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6130053A (en) *	1999-08-03	2000-10-10	Cell Pathways, Inc.	Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6303135B1 (en)	1999-07-08	2001-10-16	Neal R. Cutler	Use of quinolines and quinolones to treat male erectile dysfunction
US6555547B1 (en)	2000-02-28	2003-04-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en)	2000-03-03	2003-05-27	Cell Pathways, Inc	Method for screening compounds for the treatment of neoplasia
NZ524572A (en) *	2000-09-06	2004-08-27	Tanabe Seiyaku Co	Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
US6562838B2 (en)	2001-01-26	2003-05-13	R. T. Alamo Ventures I, L.L.C.	Treatment of cardiovascular disease with quinolinone enantiomers
US7927623B2 (en)	2001-02-15	2011-04-19	Mitsubishi Tanabe Pharma Corporation	Tablets quickly disintegrated in oral cavity
AU2002337428A1 (en) *	2001-11-30	2003-06-10	Pfizer Products Inc.	Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003250701A1 (en)	2002-07-31	2004-02-16	Wayne R. Danter	Protein tyrosine kinase inhibitors
CA2542007C (en)	2002-10-09	2010-06-29	Wayne R. Danter	Protein tyrosine kinase inhibitors
EP1578757B1 (en)	2002-12-27	2014-10-22	Janssen Infectious Diseases BVBA	Fluorogenic enzyme substrates and methods of preparation
CN100506802C (zh) *	2004-06-04	2009-07-01	中国科学院上海药物研究所	一类甲酰肽样受体-1调节剂、其制备方法和用途
AU2007303846B2 (en) *	2006-10-04	2011-03-10	Pfizer Products Inc.	Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
EP2121681B1 (en)	2007-01-11	2015-04-15	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN101429166B (zh) *	2007-11-07	2013-08-21	上海特化医药科技有限公司	喹唑啉酮衍生物及其制备方法和用途
EP2225226B1 (en)	2007-12-26	2016-08-17	Critical Outcome Technologies, Inc.	Compounds and their use in a method for treatment of cancer
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2999321A1 (en)	2008-07-17	2010-01-21	Critical Outcome Technologies Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
US20100221329A1 (en)	2008-12-03	2010-09-02	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase c agonists and methods of use
EP2552915B1 (en)	2010-04-01	2017-07-19	Critical Outcome Technologies Inc.	Compounds for the treatment of hiv
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
JP6393037B2 (ja)	2010-09-15	2018-09-19	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼｃアゴニストの製剤および使用方法
WO2014151206A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2015209143A1 (en) *	2014-01-23	2016-08-04	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Icariin derivatives
US10300042B2 (en)	2014-06-23	2019-05-28	Celgene Corporation	Apremilast for the treatment of a liver disease or a liver function abnormality
CN110590769B (zh) *	2019-06-13	2021-09-24	中山大学	一对喹唑啉酮生物碱对映体及其制备方法和应用
WO2024026424A1 (en) *	2022-07-27	2024-02-01	Black Diamond Therapeutics, Inc.	Quinazolinone derivatives as and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3169129A (en) *	1963-05-10	1965-02-09	American Cyanamid Co	2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US4431440A (en) *	1981-02-20	1984-02-14	American Cyanamid Company	Method to alter or control the development and/or the life cycle of various plant species
GB9126260D0 (en) *	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5294612A (en) *	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

1995
- 1995-01-19 DE DE19501481A patent/DE19501481A1/de not_active Withdrawn
- 1995-12-26 IN IN2408DE1995 patent/IN184956B/en unknown
1996
- 1996-01-05 HR HR19501481.2A patent/HRP960004A2/hr not_active Application Discontinuation
- 1996-01-08 EP EP96100154A patent/EP0722937A1/de not_active Withdrawn
- 1996-01-11 US US08/584,865 patent/US5721238A/en not_active Expired - Fee Related
- 1996-01-12 YU YU1496A patent/YU1496A/sh unknown
- 1996-01-15 TR TR96/00029A patent/TR199600029A2/xx unknown
- 1996-01-15 AU AU40980/96A patent/AU704102B2/en not_active Ceased
- 1996-01-16 IL IL11677096A patent/IL116770A/xx active IP Right Grant
- 1996-01-16 RO RO96-00077A patent/RO117451B1/ro unknown
- 1996-01-16 CA CA002167345A patent/CA2167345A1/en not_active Abandoned
- 1996-01-16 NZ NZ280831A patent/NZ280831A/en unknown
- 1996-01-17 FI FI960227A patent/FI960227A/fi unknown
- 1996-01-17 PL PL96312352A patent/PL312352A1/xx unknown
- 1996-01-17 SG SG1996000263A patent/SG34377A1/en unknown
- 1996-01-17 JP JP8022973A patent/JPH08253457A/ja active Pending
- 1996-01-18 EE EE9600019A patent/EE9600019A/xx unknown
- 1996-01-18 KR KR1019960001004A patent/KR960029325A/ko not_active Application Discontinuation
- 1996-01-18 NO NO960222A patent/NO307513B1/no unknown
- 1996-01-18 RU RU96100854/04A patent/RU2158733C2/ru active
- 1996-01-18 BR BR9600148A patent/BR9600148A/pt active Search and Examination
- 1996-01-18 CZ CZ96167A patent/CZ16796A3/cs unknown
- 1996-01-18 MA MA24135A patent/MA23780A1/fr unknown
- 1996-01-18 BG BG100293A patent/BG100293A/xx unknown
- 1996-01-18 ZA ZA96397A patent/ZA96397B/xx unknown
- 1996-01-18 SK SK77-96A patent/SK7796A3/sk unknown
- 1996-01-19 AR ARP960101087A patent/AR006738A1/es unknown
- 1996-01-19 SV SV1996000005A patent/SV1996000005A/es unknown
- 1996-01-19 PE PE1996000044A patent/PE66696A1/es not_active Application Discontinuation
- 1996-01-19 CO CO96002168A patent/CO4700522A1/es unknown
- 1996-01-19 HU HU9600114A patent/HUP9600114A3/hu unknown
- 1996-01-19 CN CN96101906A patent/CN1134417A/zh active Pending

Also Published As

Publication number	Publication date
IN184956B (hu)	2000-10-07
ZA96397B (en)	1996-08-28
EE9600019A (et)	1996-08-15
AU704102B2 (en)	1999-04-15
NO307513B1 (no)	2000-04-17
CA2167345A1 (en)	1996-07-20
PL312352A1 (en)	1996-07-22
EP0722937A1 (de)	1996-07-24
PE66696A1 (es)	1997-03-09
JPH08253457A (ja)	1996-10-01
IL116770A0 (en)	1996-05-14
SK7796A3 (en)	1996-08-07
HU9600114D0 (en)	1996-03-28
HUP9600114A2 (en)	1996-12-30
US5721238A (en)	1998-02-24
RO117451B1 (ro)	2002-03-29
FI960227A (fi)	1996-07-20
RU2158733C2 (ru)	2000-11-10
AU4098096A (en)	1996-07-25
YU1496A (sh)	1998-09-18
CO4700522A1 (es)	1998-12-29
BG100293A (en)	1996-07-31
NO960222D0 (no)	1996-01-18
CZ16796A3 (en)	1996-08-14
NO960222L (no)	1996-07-22
AR006738A1 (es)	1999-09-29
FI960227A0 (fi)	1996-01-17
HRP960004A2 (en)	1998-02-28
CN1134417A (zh)	1996-10-30
BR9600148A (pt)	1998-01-06
DE19501481A1 (de)	1996-07-25
SV1996000005A (es)	1997-03-11
IL116770A (en)	2000-08-31
SG34377A1 (en)	1996-12-06
KR960029325A (ko)	1996-08-17
NZ280831A (en)	1996-10-28
TR199600029A2 (tr)	1996-08-21
MA23780A1 (fr)	1996-10-01

Publication	Publication Date	Title
HUP9600114A3 (en)	2000-03-28	2,8-disubstituted quinazolinones and pharmaceutical compositions containing them
HUS1400001I1 (hu)	2016-02-29	Kinazolin származékok, azok elõállítása, valamint a vegyületeket tartalmazó gyógyszerkészítmények
IL119078A (en)	2003-11-23	Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL121621A0 (en)	1998-02-08	Neurotrophic compounds pharmaceutical compositions containing them and their use
IL116851A (en)	2000-06-01	3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
IL109315A0 (en)	1994-07-31	1, 5-benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
IL119488A (en)	2001-01-11	Substituted 2, 4-imidazolidinediones, their production and pharmaceutical compositions containing them
AP9701160A0 (en)	1998-01-31	Compounds and pharmaceutical compositions containing them
ZA967827B (en)	1997-03-18	Pharmaceutical compositions
IL135723A (en)	2005-11-20	1'-Ä4-Ä1-4-Fluorophenyl)-1H-indole-3-ylÜ-1-butylÜ-spiroÄisobenzofuran-1-(3H),4'-piperidineÜhydrohal ogenides and pharmaceutical compositions containing them
HUT73499A (en)	1996-08-28	1,5-benzodiazepine derivatives and pharmaceutical compositions containing them
HUP9602196A2 (en)	1997-05-28	Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
EG24294A (en)	2009-01-08	Pharmaceutical compositions
IL110809A0 (en)	1994-11-11	1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
GB9506382D0 (en)	1995-05-17	Pharmaceutical compositions
GB9513972D0 (en)	1995-09-06	Pharmaceutical compositions
HUP9903526A3 (en)	2000-07-28	Pyrimidine derivatives and pharmaceutical compositions containing the same
IL117806A0 (en)	1996-08-04	1,3-Dihydro-2h-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them
GB9502695D0 (en)	1995-03-29	Pharmaceutical composition
HUP9802291A3 (en)	1999-06-28	Penicillaminamide derivatives and pharmaceutical compositions containing them
IL124415A (en)	2003-11-23	N, n'-bridged bisindolylmaleimides, their preparation and pharmaceutical compositions containing them
IL117618A0 (en)	1996-07-23	Diphenylmethyl-azetidinone derivatives and pharmaceutical compositions containing the same
IL117155A0 (en)	1996-06-18	Quinolizinone derivatives and pharmaceutical compositions containing the same
HUP9802072A3 (en)	2000-01-28	Benzothiopyranoindazole derivatives and pharmaceutical compositions containing them
ZA968616B (en)	1997-05-13	Pharmaceutical composition